PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

BACKGROUND: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free survival (iDFS) in women who completed trastuzumab...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res
Autores principales: Chia, Stephen K. L., Martin, Miguel, Holmes, Frankie A., Ejlertsen, Bent, Delaloge, Suzette, Moy, Beverly, Iwata, Hiroji, von Minckwitz, Gunter, Mansi, Janine, Barrios, Carlos H., Gnant, Michael, Tomašević, Zorica, Denduluri, Neelima, Šeparović, Robert, Kim, Sung-Bae, Jakobsen, Erik Hugger, Harvey, Vernon, Robert, Nicholas, Smith, John, Harker, Graydon, Zhang, Bo, Eli, Lisa D., Ye, Yining, Lalani, Alshad S., Buyse, Marc, Chan, Arlene
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6417207/
https://ncbi.nlm.nih.gov/pubmed/30867034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1115-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares